🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

We’re proud to be supporting the Centre for Psychedelic Research team to run the first ever study investigating the effects of BPL-003 - our novel, synthetic intranasal formulation of 5-MeO-DMT benzoate - on the human brain. Read more about the study here: beckleypsytech.com/posts/first-pa…

Co-Founders, Cosmo Feilding Mellen and Lady Amanda Feilding, chatted to @EveningStandard earlier this year to discuss the heritage, work and future of Beckley Psytech. Check out the full interview here: standard.co.uk/lifestyle/well…

Results from our Phase I study of BPL-003 in healthy volunteers have now been published in Volume 38, Issue 8 of the Journal of Psychopharmacology, showing BPL-003 can produce a rapid onset and short duration of subjective effect. Find the full paper here: journals.sagepub.com/doi/10.1177/02…

You can catch us at @ECNPtweets this week in two poster sessions that will share novel insights into the workings of BPL-003 - our novel intranasal formulation of 5-MeO-DMT benzoate. Click here to learn more: beckleypsytech.com/posts/beckley-…

Today is Global Magic Mushroom Day and we’re spotlighting our work on ELE-101, a novel, synthetic intravenous formulation of psilocin benzoate. Learn more about our Phase IIa study of ELE-101 for Major Depressive Disorder here. beckleypsytech.com/posts/beckley-…

We are at @ECNPtweets today sharing findings from our Phase IIa study of BPL-003 for TRD. In the study, BPL-003 delivered rapid and lasting antidepressant effects with a short time in clinic. Learn more on our website: beckleypsytech.com

How might next-generation psychedelics revolutionise the treatment of mental health conditions? Find out what our CEO, Cosmo Feilding Mellen, thinks in TIME today: time.com/7027173/new-ps…

Good luck to Anya Ermakova, Research Scientist at Beckley Psytech, who will be sharing her microphenomenology research from our Phase I study of BPL-003 at Mind and Life Europe’s event ‘Becoming Aware and Micro-Phenomenology: Process, Practice, Outcomes’ this weekend.

Today is #WorldMentalHealthDay! We spoke with our CSMO, Dr. Rob Conley, about the latest in mental health treatments for depression & substance use disorders - and his hopes for the future. Read the full Q+A here: beckleypsytech.com/posts/what-doe…

How do you progress a psychedelic-based treatment through development and onto patients in need? Find out in the 'Power to the Patients' with our CEO, Cosmo Feilding Mellen, and Brandon Li. Full episode here: youtube.com/watch?v=W7AVkN…

In this fascinating interview, Cosmo Feilding Mellen shares his journey from growing up at the heart of the psychedelic revolution to leading the charge in plant-based medicine. YT: twtr.to/V--Ij Spotify: twtr.to/ci3DW Apple: twtr.to/YLOZA

ICYMI: Our CEO, Cosmo Feilding Mellen, caught up with TIME to discuss how our novel short-acting, psychedelic-based therapies could revolutionise the treatment of mental health conditions. Learn more here: time.com/7027173/new-ps…

🎙️ In this fascinating episode of The Healthtech Podcast with Dr. James Somauroo, our CEO, Cosmo Feilding Mellen, shares his insights on psychedelics, consciousness, and mental health innovation. 🎧 Listen here: open.spotify.com/episode/3EdURo…

Initial findings from our Phase IIa study of ELE-101 for depression shows that a single 10-minute infusion is well-tolerated, induces rapid and lasting antidepressant effects, and allows patients to be ready for discharge in ~2 hours. Read more here: t.ly/mGgPP

Topline data from our Phase IIa study of BPL-003 for Alcohol Use Disorder show that a single dose was well-tolerated and delivered a meaningful and sustained reduction in alcohol use and Heavy Drinking Days over a 3-month evaluation period. beckleypsytech.com/posts/beckley-…

Today is International Day of Women and Girls in Science! 🌍🔬 At Beckley Psytech, we’re celebrating the brilliant women in our team who are shaping the future of science. Hear about some of their experiences below. #IDWGS #WomenInSTEM

We have completed enrolment in the core stage of our Phase IIb study of BPL-003 for Treatment Resistant Depression. Grateful to our trial participants & partners who made this study happen! beckleypsytech.com/posts/beckley-…

It's Brain Awareness Week - the perfect time to highlight the first-of-its-kind brain imaging study going on at Imperial College London with BPL-003. Check out our Q&A with the experts behind the study (Chris Timmermann, Tommaso Barba) below.

We will be presenting data from our Phase IIa study of BPL-003 for TRD at #SOBP2025 in Toronto tomorrow at 5pm EDT. Looking forward to connecting with the scientific community. beckleypsytech.com/posts/beckley-…

Today we announced positive topline results from our Phase IIa study of BPL-003 in combination with SSRIs for treatment resistant depression. Read more on our website: beckleypsytech.com/posts/positive…